/PRNewswire/ NovoMedix, LLC ("NovoMedix"), a biotechnology company developing novel, multi-pathway modulators for fibrosis and cancer, today announced the.
The NIH has awarded NovoMedix a $2m Phase II SBIR grant to further the development of novel small molecules that protect patients with triple-negative breast cancer (TNBC) from the long-term cardiotoxic impacts of doxorubicin chemotherapy.
/PRNewswire/ NovoMedix, LLC ("NovoMedix"), a biotechnology company creating novel, safe, and effective drugs to treat unmet medical needs, today announced.